Galectin-7 reprograms skin carcinogenesis by fostering innate immune evasive programs
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Galectin-7 reprograms skin carcinogenesis by fostering innate immune evasive programs. / Pinto, Nicolás A.; Abba, Martín C.; Laporte, Lorena; Pérez Sáez, Juan M.; Blidner, Ada G.; Torres, Nicolás I.; Morales, Rosa M.; Gatto, Sabrina G.; Bach, Camila A.; Veigas, Florencia; García Rivello, Hernán J.; Song, Peng; Frederiksen, Jane H.; Rasmussen, Lene Juel; Poirier, Francoise; Croci, Diego O.; Sundblad, Victoria; Rabinovich, Gabriel A.; Cerliani, Juan P.
In: Cell Death and Differentiation, Vol. 30, 2023, p. pages906–921.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Galectin-7 reprograms skin carcinogenesis by fostering innate immune evasive programs
AU - Pinto, Nicolás A.
AU - Abba, Martín C.
AU - Laporte, Lorena
AU - Pérez Sáez, Juan M.
AU - Blidner, Ada G.
AU - Torres, Nicolás I.
AU - Morales, Rosa M.
AU - Gatto, Sabrina G.
AU - Bach, Camila A.
AU - Veigas, Florencia
AU - García Rivello, Hernán J.
AU - Song, Peng
AU - Frederiksen, Jane H.
AU - Rasmussen, Lene Juel
AU - Poirier, Francoise
AU - Croci, Diego O.
AU - Sundblad, Victoria
AU - Rabinovich, Gabriel A.
AU - Cerliani, Juan P.
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Non-melanoma skin cancer (NMSC) has risen dramatically as a result of chronic exposure to sunlight ultraviolet (UV) radiation, climatic changes and clinical conditions associated with immunosuppression. In spite of considerable progress, our understanding of the mechanisms that control NMSC development and their associated molecular and immunological landscapes is still limited. Here we demonstrated a critical role for galectin-7 (Gal-7), a β-galactoside-binding protein preferentially expressed in skin tissue, during NMSC development. Transgenic mice (Tg46) overexpressing Gal-7 in keratinocytes showed higher number of papillomas compared to WT mice or mice lacking Gal-7 (Lgals7−/−) when subjected to a skin carcinogenesis protocol, in which tumor initiator 7,12-dimethylbenz[a]anthracene (DMBA) and tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA) were sequentially administered. RNAseq analysis of Tg46 tumor lesions revealed a unique profile compatible with cells of the myelomonocytic lineage infiltrating these tumors, an effect that was substantiated by a higher number of CD11b+Gr1+ cells in tumor-draining lymph nodes. Heightened c-Met activation and Cxcl-1 expression in Tg46 lesions suggested a contribution of this pathway to the recruitment of these cells. Remarkably, Gal-7 bound to the surface of CD11b+Ly6ChiLy6Glo monocytic myeloid cells and enhanced their immunosuppressive activity, as evidenced by increased IL-10 and TGF-β1 secretion, and higher T-cell inhibitory activity. In vivo, carcinogen-treated Lgals7−/− animals adoptively transferred with Gal-7-conditioned monocytic myeloid cells developed higher number of papillomas, whereas depletion of these cells in Tg46-treated mice led to reduction in the number of tumors. Finally, human NMSC biopsies showed increased LGALS7 mRNA and Gal-7 protein expression and displayed transcriptional profiles associated with myeloid programs, accompanied by elevated CXCL1 expression and c-Met activation. Thus, Gal-7 emerges as a critical mediator of skin carcinogenesis and a potential therapeutic target in human NMSC.
AB - Non-melanoma skin cancer (NMSC) has risen dramatically as a result of chronic exposure to sunlight ultraviolet (UV) radiation, climatic changes and clinical conditions associated with immunosuppression. In spite of considerable progress, our understanding of the mechanisms that control NMSC development and their associated molecular and immunological landscapes is still limited. Here we demonstrated a critical role for galectin-7 (Gal-7), a β-galactoside-binding protein preferentially expressed in skin tissue, during NMSC development. Transgenic mice (Tg46) overexpressing Gal-7 in keratinocytes showed higher number of papillomas compared to WT mice or mice lacking Gal-7 (Lgals7−/−) when subjected to a skin carcinogenesis protocol, in which tumor initiator 7,12-dimethylbenz[a]anthracene (DMBA) and tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA) were sequentially administered. RNAseq analysis of Tg46 tumor lesions revealed a unique profile compatible with cells of the myelomonocytic lineage infiltrating these tumors, an effect that was substantiated by a higher number of CD11b+Gr1+ cells in tumor-draining lymph nodes. Heightened c-Met activation and Cxcl-1 expression in Tg46 lesions suggested a contribution of this pathway to the recruitment of these cells. Remarkably, Gal-7 bound to the surface of CD11b+Ly6ChiLy6Glo monocytic myeloid cells and enhanced their immunosuppressive activity, as evidenced by increased IL-10 and TGF-β1 secretion, and higher T-cell inhibitory activity. In vivo, carcinogen-treated Lgals7−/− animals adoptively transferred with Gal-7-conditioned monocytic myeloid cells developed higher number of papillomas, whereas depletion of these cells in Tg46-treated mice led to reduction in the number of tumors. Finally, human NMSC biopsies showed increased LGALS7 mRNA and Gal-7 protein expression and displayed transcriptional profiles associated with myeloid programs, accompanied by elevated CXCL1 expression and c-Met activation. Thus, Gal-7 emerges as a critical mediator of skin carcinogenesis and a potential therapeutic target in human NMSC.
U2 - 10.1038/s41418-022-01108-7
DO - 10.1038/s41418-022-01108-7
M3 - Journal article
C2 - 36693903
AN - SCOPUS:85146680235
VL - 30
SP - 906
EP - 921
JO - Cell Differentiation and Development
JF - Cell Differentiation and Development
SN - 1350-9047
ER -
ID: 337597051